Loading...
About Akloma 2017-12-05T19:19:09+00:00

Akloma Bioscience AB is a Swedish company dedicated to delivering breakthrough solutions in healthcare addressing medical, smart packaging and functional water research worldwide. The company is based on more than 15 years of scientific research where Aklotech® is the core technology behind all scientific projects and is patent registrated.

The company is pressing forward with development of cutting-edge technologies to create collaborative businesses, aiming to release an expansible business portfolio and ultimately sustainable growth. The high qualified competences has contributed to the research, commercialisation and IPO of a medical device that was introduced internationally.

Members of the Board

Joachim Hjerpe

Chairman of the Board

Former Vice President at AB Volvo and an experienced expert on strategy, business development and operational management. CEO of United Sun Systems AB. Mr. Hjerpe has a MBA; Chalmers University of Technology, Gothenburg

David Pursell

Member of the Board

Mr Pursell is a former Manager of a property development company in England, focusing on large industrial sites, and a former Chartered Accountant with own private practice in the UK. He is an investor and advisor to Akloma.

Anders Nordkvist

Member of the Board

MD, Ph.D. 20 years as ENT Senior Specialist, with the past 10 years serving in the capacity as chief medical officer, founder and owner of Gothenburg City Hospital

Benny Johansson

Member of the Board

Ph.D. in Experimental Clinical Chemistry and a Master Degree of Science in Biochemistry. Senior Research Scientist at Scandinavian International University at Örebro. Dr. Johansson has previously worked at the Institute of Clinical Chemistry at SUS, Malmö, Sweden and at AstraZeneca.

Ebbe Damm

Member of the Board

Member of the board and Co-founder Mr. Damm has extensive diverse experience in the fields of corporate management and business development Mr. Damm has his expertise in financial transactions, corporate investment strategy, and corporate management.

Management Team

Jörgen Ringman

CEO

Executive MBA health – Stockholm School of Economics. Authorised Optometrist – Karolinska Institutet, Stockholm. Extensive experience within strategy, business development & corporate investment. Member of the board and Co-founder of Memira Holding AB, Founder of ‘Coherent City’

Ebbe Damm

CFO

Member of the board and Co-founder Mr. Damm has extensive diverse experience in the fields of corporate management and business development Mr. Damm has his expertise in financial transactions, corporate investment strategy, and corporate management.

Benny Johansson

Chief Scientific Officer

Ph.D. in Experimental Clinical Chemistry and a Master Degree of Science in Biochemistry. Senior Research Scientist at Scandinavian International University at Örebro. Dr. Johansson has previously worked at the Institute of Clinical Chemistry at SUS, Malmö, Sweden and at AstraZeneca.

Charlotte Bäcklin

Corporate Identity, Product Development, Market analysis and Branding

Master of Science in Digital Commercialisation, Aden Business School, Argentina

Nikolaj Blom

Quantum Biologist

MSc in Biochemistry from University of Copenhagen and PhD in Bioinformatics from the Technical University of Denmark. Experienced associate professor and senior manager at Novozymes A/S, NsGene A/S and Display Systems Biotech. Explorer on two polar expeditions.

Björn Nyberg

Marketing strategist

Marketing strategist within the FMCG and lifestyle sectors. Has previously worked within strategy development for brands such as Absolut, Kronaby, Wyborowa, ICA supermarkets.

Policies and Strategies

Code of ethics

Our business is focused on research and development aimed at providing quality-improving products and technologies in the medical, smart packaging and functional water fields as well as other novel technologies.

Quality Policy

Akloma will identify and adapt AKLO technology for applications in the food and beverage industry and medical technology applications. By continuously taking into account the customers’ views and identifying improvements, Akloma strives to pursue an activity that continually increases customer satisfaction and confidence in Akloma and Akloma’s technology and services. In addition, Akloma and Akloma’s services shall always comply with applicable regulatory requirements. In order to achieve this, Akloma will ensure that all the persons connected to the company are aware of these requirements and strive to fulfil them.

Regulatory status

Akloma has developed a quality management system and a technical file for the product to meet regulatory requirements of the MDD directive – External quality management advisors: SYMBIOTEQ AB. Registered certification according to both MDD and ISO 13485:2003. ISO certification was approved in January 2011. External certification by Intertek- SEMKO

The Patent Strategy

An important part of Akloma Bioscience’s strategy involves protecting know-how through strong patents. Patent protection covers the discovery of methods and processes, as well as user areas and products on a global basis. A patent entails exclusive rights to make commercial use of a discovery. Strong patent protection is thus a pre-requisite for a company such as Akloma to invest in developing and commercialising a product.

Akloma Bioscience AB Technology patent application

  • 

A Swedish and a US provisional application filed in February of 2007.
  • A PCT application SE2008/000119 filed in February of 2009, since fall 2009 in regional and national phases. US, China, Japan, Israel, Russia, Canada, Australia, South Korea, New Zealand, India, South Africa, as well as with the EPO. Patent granted in South Africa.
  • A follow-up Swedish application was field in June 2016 focused on new applications based on further development of the Aklo technology.

External patent Council

AWA patent is the Company’s external patent counsel.